Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
sulfacetamidnatrium 10 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Sulfacetamide sodium 10% ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release eye solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Sulfacetamide sodium 150 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
phenylephrinhydrochlorid 1,25 mg + sulfacetamidnatrium 150 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat + sulfacetamidnatrium 0,2 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Prednisolone acetate 2 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat + sulfacetamidnatrium 0,25 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonnatriumphosphat 2,5 mg + sulfacetamidnatrium 100 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
phenylephrinhydrochlorid + sulfacetamidnatrium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
sulfacetamid 10 % øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat + sulfacetamidnatrium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
prednisolonacetat 0,5 % wt/wt + sulfacetamidnatrium 10 % wt/wt salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
sulfacetamidsulfat + svovl |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfacetamide sodium |
Inferred relationship |
Some |
|
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release eye solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release eye solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 150 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 150 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely fluorometholone 1 milligram/1 milliliter and sulfacetamide sodium 100 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely fluorometholone 1 milligram/1 milliliter and sulfacetamide sodium 100 milligram/1 milliliter conventional release eye suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely sulfacetamide sodium 300 milligram/1 milliliter conventional release eye solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Product containing precisely sulfacetamide sodium 300 milligram/1 milliliter conventional release eye solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 100 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 100 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 200 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 200 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 60 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 60 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 25 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfacetamide sodium 25 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Prednisolone acetate 2 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Prednisolone acetate 2 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfacetamide sodium |
Inferred relationship |
Some |
1 |